Prostate cancer – major changes in the American Joint Committee on Cancer eighth edition cancer staging manual

Citations Over TimeTop 1% of 2017 papers

Abstract

Answer questions and earn CME/CNE The eighth edition of the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) Staging Manual has been updated and improved to ensure the highest degree of clinical relevance and to improve its utility for patient evaluation and clinical research. Major changes include: 1) pathologically organ-confined disease is now considered pT2 and is no longer subclassified by extent of involvement or laterality, 2) tumor grading now includes both the Gleason score (as in the seventh edition criteria) and the grade group (introduced in the eighth edition criteria), 3) prognostic stage group III includes select, organ-confined disease based on prostate-specific antigen and Gleason/grade group status, and 4) 2 statistical prediction models are included in the staging manual. The AJCC will continue to critically analyze emerging prostate cancer biomarkers and tools for their ability to prognosticate and guide treatment decision making with the highest level of accuracy and confidence for patients and physicians. CA Cancer J Clin 2017;67:245-253. © 2017 American Cancer Society.

Related Papers

• → DEFINING PROSTATE SPECIFIC ANTIGEN PROGRESSION AFTER RADICAL PROSTATECTOMY: WHAT IS THE MOST APPROPRIATE CUT POINT?(2001)408 cited
• → Influence of radical prostatectomy on miRNA dynamics in urine extracellular vesicles(2024)3 cited
• → Prostate specific antigen nadir determined using ultra‐sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males(2007)14 cited
• → ULTRASENSITIVE DETECTION OF PROSTATE SPECIFIC ANTIGEN IN THE FOLLOWUP OF 422 PATIENTS AFTER RADICAL PROSTATECTOMY(1999)4 cited
• → Editorial Comment(2010)